Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Jul;80(9):1387–1391. doi: 10.1038/sj.bjc.6690533

A phase I/II study of combined weekly systemic cisplatin and locoregional hyperthermia in patients with previously irradiated recurrent carcinoma of the uterine cervix

R de Wit 1, J van der Zee 2, M E L van der Burg 1, W H Kruit 1, A Logmans 2,1, G C van Rhoon 2, J Verweij 1
PMCID: PMC2363069  PMID: 10424740

Abstract

We investigated the feasibility and the anti-tumour activity of weekly cisplatin and the simultaneous application of local hyperthermia in patients with a pelvic recurrence of cervical cancer in previously irradiated area. Dose levels of cisplatin 60 mg m−2, 70 mg m−2 and 80 mg m−2 were studied. Treatment objective of hyperthermia was the achievement of a tumour temperature of ≥ 42° for 60 min, during cisplatin administration. The protocol advised six weekly cycles of combined treatment. Nineteen patients, median age 47 years (range 26–71), were treated. A total of 89 cycles of combined treatment were administered. Even at the highest dose level of cisplatin, 80 mg m−2 weekly, no dose-limiting toxicity was observed. Leucocytopenia at scheduled retreatment resulted in 1 or 2 weeks postponement in five cases. Neurotoxicity and renal toxicity were mild or absent. Maximum tumour temperatures achieved ranged 39.7–43.6°C, mean 41.6 ± 0.7°C. All 19 patients were evaluable for response. One patient achieved a complete response that lasted 20 months, and nine patients achieved a partial response for a median duration of 6 months (range 4–50+ months), for an overall response rate of 53%. One patient subsequently underwent salvage surgery and currently remains free of disease at 4 years. We found that this combined hyperthermia- dose-intensive cisplatin regimen was well-tolerated. The true impact of the combination of cisplatin and locoregional hyperthermia can only be answered in a randomized study. Nonetheless, based on existing data on the poor efficacy of cisplatin in pelvic recurrent cervical cancer, we believe that the combined modality approach of weekly hyperthermia plus dose-intensive cisplatin is an attractive regimen, particularly if subsequent salvage surgery is available. © 1999 Cancer Research Campaign

Keywords: cervical cancer, cisplatin chemotherapy, hyperthermia

Full Text

The Full Text of this article is available as a PDF (56.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baba H., Siddik Z. H., Strebel F. R., Jenkins G. N., Bull J. M. Increased therapeutic gain of combined cis-diamminedichloroplatinum (II) and whole body hyperthermia therapy by optimal heat/drug scheduling. Cancer Res. 1989 Dec 15;49(24 Pt 1):7041–7044. [PubMed] [Google Scholar]
  2. Brader K. R., Morris M., Levenback C., Levy L., Lucas K. R., Gershenson D. M. Chemotherapy for cervical carcinoma: factors determining response and implications for clinical trial design. J Clin Oncol. 1998 May;16(5):1879–1884. doi: 10.1200/JCO.1998.16.5.1879. [DOI] [PubMed] [Google Scholar]
  3. Green D. M., Burton G. V., Cox E. B., Hanson D., Moore J., Oleson J. R. A phase I/II study of combined cisplatin and hyperthermia treatment for refractory malignancy. Int J Hyperthermia. 1989 Jan-Feb;5(1):13–21. doi: 10.3109/02656738909140429. [DOI] [PubMed] [Google Scholar]
  4. Lele S. B., Piver M. S. Weekly cisplatin induction chemotherapy in the treatment of recurrent cervical carcinoma. Gynecol Oncol. 1989 Apr;33(1):6–8. doi: 10.1016/0090-8258(89)90594-5. [DOI] [PubMed] [Google Scholar]
  5. Osmak M., Perovic S. Multiple fractions of gamma rays induced resistance to cis-dichloro-diammineplatinum (II) and methotrexate in human HeLa cells. Int J Radiat Oncol Biol Phys. 1989 Jun;16(6):1537–1541. doi: 10.1016/0360-3016(89)90959-0. [DOI] [PubMed] [Google Scholar]
  6. Planting A. S., de Mulder P. H., de Graeff A., Verweij J. Phase II study of weekly high-dose cisplatin for six cycles in patients with locally advanced squamous cell carcinoma of the head and neck. Eur J Cancer. 1997 Jan;33(1):61–65. doi: 10.1016/s0959-8049(96)00311-5. [DOI] [PubMed] [Google Scholar]
  7. Planting A. S., van der Burg M. E., de Boer-Dennert M., Stoter G., Verweij J. Phase I/II study of a short course of weekly cisplatin in patients with advanced solid tumours. Br J Cancer. 1993 Oct;68(4):789–792. doi: 10.1038/bjc.1993.429. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Potter M. E., Hatch K. D., Potter M. Y., Shingleton H. M., Baker V. V. Factors affecting the response of recurrent squamous cell carcinoma of the cervix to cisplatin. Cancer. 1989 Apr 1;63(7):1283–1286. doi: 10.1002/1097-0142(19890401)63:7<1283::aid-cncr2820630709>3.0.co;2-u. [DOI] [PubMed] [Google Scholar]
  9. Rietbroek R. C., Bakker P. J., Schilthuis M. S., Postma A. J., Zum Vörde Sive Vording P. J., Gonzalèz Gonzalèz D., Kurth K. H., Bakker A. J., Veenhof C. H. Feasibility, toxicity, and preliminary results of weekly loco-regional hyperthermia and cisplatin in patients with previously irradiated recurrent cervical carcinoma or locally advanced bladder cancer. Int J Radiat Oncol Biol Phys. 1996 Mar 1;34(4):887–893. doi: 10.1016/0360-3016(95)02152-3. [DOI] [PubMed] [Google Scholar]
  10. Rietbroek R. C., Schilthuis M. S., Bakker P. J., van Dijk J. D., Postma A. J., González González D., Bakker A. J., van der Velden J., Helmerhorst T. J., Veenhof C. H. Phase II trial of weekly locoregional hyperthermia and cisplatin in patients with a previously irradiated recurrent carcinoma of the uterine cervix. Cancer. 1997 Mar 1;79(5):935–943. doi: 10.1002/(sici)1097-0142(19970301)79:5<935::aid-cncr10>3.0.co;2-3. [DOI] [PubMed] [Google Scholar]
  11. Turner P. F., Schaefermeyer T. BSD-2000 approach for deep local and regional hyperthermia: clinical utility. Strahlenther Onkol. 1989 Oct;165(10):700–704. [PubMed] [Google Scholar]
  12. Wallner K. E., DeGregorio M. W., Li G. C. Hyperthermic potentiation of cis-diamminedichloroplatinum(II) cytotoxicity in Chinese hamster ovary cells resistant to the drug. Cancer Res. 1986 Dec;46(12 Pt 1):6242–6245. [PubMed] [Google Scholar]
  13. Wallner K. E., Li G. C. Effect of drug exposure duration and sequencing on hyperthermic potentiation of mitomycin-C and cisplatin. Cancer Res. 1987 Jan 15;47(2):493–495. [PubMed] [Google Scholar]
  14. van der Zee J., Peer-Valstar J. N., Rietveld P. J., de Graaf-Strukowska L., van Rhoon G. C. Practical limitations of interstitial thermometry during deep hyperthermia. Int J Radiat Oncol Biol Phys. 1998 Mar 15;40(5):1205–1212. doi: 10.1016/s0360-3016(98)00008-x. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES